25million patients worldwide with heart failure, market big enough for multiple devices/treatments for all class levels requiring treatment.
Implulse Dynamics failed its primary endpoint in its US Pivotal IDE Trial but did have positive data in a sub group of patients.
However, since this group was looked at only retrospectively, the FDA is requiring another trial which is currently recruiting.
25million patients worldwide with heart failure, market big...
Add to My Watchlist
What is My Watchlist?